Neoprobe initiates third multi-center Phase 3 clinical study of Lymphoseek

[News]

Neoprobe Corporation, a diversified developer of innovative oncology surgical and diagnostic products, today announced that a third multi-center Phase 3 clinical study of Lymphoseek (NEO3-09) has received investigational review board approval and begun enrollment of subjects diagnosed with breast cancer or melanoma.

More... (http://www.news-medical.net/news/20100707/Neoprobe-initiates-third-multi-center-Phase-3-clinical-study-of-Lymphoseek.aspx)